Meridian Bioscience (NASDAQ:VIVO) had its price target reduced by Robert W. Baird from $17.00 to $14.00 in a research report released on Wednesday, The Fly reports. Robert W. Baird currently has a neutral rating on the stock.

A number of other brokerages also recently weighed in on VIVO. BidaskClub downgraded shares of Meridian Bioscience from a strong-buy rating to a buy rating in a report on Saturday, December 15th. ValuEngine upgraded shares of Meridian Bioscience from a hold rating to a buy rating in a report on Friday, March 29th. Finally, Zacks Investment Research downgraded shares of Meridian Bioscience from a buy rating to a hold rating in a report on Wednesday, March 20th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $14.75.

Shares of NASDAQ VIVO traded up $0.25 during midday trading on Wednesday, reaching $13.54. The company’s stock had a trading volume of 7,690 shares, compared to its average volume of 347,511. The company has a quick ratio of 4.72, a current ratio of 6.75 and a debt-to-equity ratio of 0.24. Meridian Bioscience has a fifty-two week low of $13.06 and a fifty-two week high of $19.84. The company has a market capitalization of $603.35 million, a PE ratio of 18.25 and a beta of 0.49.

Meridian Bioscience (NASDAQ:VIVO) last issued its earnings results on Thursday, January 24th. The company reported $0.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.18 by $0.02. The business had revenue of $51.48 million for the quarter, compared to the consensus estimate of $51.50 million. Meridian Bioscience had a net margin of 12.06% and a return on equity of 19.17%. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.15 earnings per share. As a group, sell-side analysts expect that Meridian Bioscience will post 0.63 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in shares of Meridian Bioscience by 1.1% in the fourth quarter. BlackRock Inc. now owns 6,295,660 shares of the company’s stock valued at $109,294,000 after acquiring an additional 67,044 shares during the period. Vanguard Group Inc. boosted its position in shares of Meridian Bioscience by 2.2% in the third quarter. Vanguard Group Inc. now owns 4,347,959 shares of the company’s stock valued at $64,784,000 after acquiring an additional 94,180 shares during the period. Vanguard Group Inc boosted its position in shares of Meridian Bioscience by 2.2% in the third quarter. Vanguard Group Inc now owns 4,347,959 shares of the company’s stock valued at $64,784,000 after acquiring an additional 94,180 shares during the period. Renaissance Technologies LLC boosted its position in shares of Meridian Bioscience by 6.5% in the third quarter. Renaissance Technologies LLC now owns 2,801,208 shares of the company’s stock valued at $41,738,000 after acquiring an additional 169,932 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Meridian Bioscience by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,901,563 shares of the company’s stock valued at $33,011,000 after acquiring an additional 14,871 shares during the period. 93.06% of the stock is owned by hedge funds and other institutional investors.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Further Reading: How is the LIBOR rate calculated?

The Fly

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.